China Resources Boya Bio pharmaceutical Group Co Ltd (300294) - Total Assets
Based on the latest financial reports, China Resources Boya Bio pharmaceutical Group Co Ltd (300294) holds total assets worth CN¥8.73 Billion CNY (≈ $1.28 Billion USD) as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See China Resources Boya Bio pharmaceutical (300294) shareholders funds for net asset value and shareholders' equity analysis.
China Resources Boya Bio pharmaceutical Group Co Ltd - Total Assets Trend (2008–2024)
This chart illustrates how China Resources Boya Bio pharmaceutical Group Co Ltd's total assets have evolved over time, based on quarterly financial data.
China Resources Boya Bio pharmaceutical Group Co Ltd - Asset Composition Analysis
Current Asset Composition (December 2024)
China Resources Boya Bio pharmaceutical Group Co Ltd's total assets of CN¥8.73 Billion consist of 60.2% current assets and 39.8% non-current assets.
| Asset Category | Amount (CNY) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | CN¥0.00 | 15.5% |
| Accounts Receivable | CN¥549.19 Million | 6.5% |
| Inventory | CN¥995.43 Million | 11.9% |
| Property, Plant & Equipment | CN¥0.00 | 0.0% |
| Intangible Assets | CN¥881.72 Million | 10.5% |
| Goodwill | CN¥728.00 Million | 8.7% |
Asset Composition Trend (2008–2024)
This chart illustrates how China Resources Boya Bio pharmaceutical Group Co Ltd's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of China Resources Boya Bio pharmaceutical .
Key Asset Composition Facts
- Current vs. Non-Current Assets: China Resources Boya Bio pharmaceutical Group Co Ltd's current assets represent 60.2% of total assets in 2024, a decrease from 67.2% in 2008.
- Cash Position: Cash and equivalents constituted 15.5% of total assets in 2024, up from 1.7% in 2008.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 18.0% of total assets, an increase from 8.0% in 2008.
- Asset Diversification: The largest asset category is inventory at 11.9% of total assets.
China Resources Boya Bio pharmaceutical Group Co Ltd Competitors by Total Assets
Key competitors of China Resources Boya Bio pharmaceutical Group Co Ltd based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
China Resources Boya Bio pharmaceutical Group Co Ltd - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 5.57 | 12.01 | 3.36 |
| Quick Ratio | 4.35 | 10.87 | 2.57 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | CN¥4.20 Billion | CN¥6.04 Billion | CN¥2.06 Billion |
China Resources Boya Bio pharmaceutical Group Co Ltd - Advanced Valuation Insights
This section examines the relationship between China Resources Boya Bio pharmaceutical Group Co Ltd's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 1.44 |
| Latest Market Cap to Assets Ratio | 0.15 |
| Asset Growth Rate (YoY) | 7.3% |
| Total Assets | CN¥8.40 Billion |
| Market Capitalization | $1.29 Billion USD |
Valuation Analysis
Below Book Valuation: The market values China Resources Boya Bio pharmaceutical Group Co Ltd's assets below their book value (0.15x), which may indicate investor concerns about asset quality or future growth.
Positive Asset Growth: China Resources Boya Bio pharmaceutical Group Co Ltd's assets grew by 7.3% over the past year, showing continued investment in the company's operational capacity.
Annual Total Assets for China Resources Boya Bio pharmaceutical Group Co Ltd (2008–2024)
The table below shows the annual total assets of China Resources Boya Bio pharmaceutical Group Co Ltd from 2008 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | CN¥8.40 Billion ≈ $1.23 Billion |
+7.31% |
| 2023-12-31 | CN¥7.83 Billion ≈ $1.15 Billion |
-2.54% |
| 2022-12-31 | CN¥8.03 Billion ≈ $1.18 Billion |
+5.40% |
| 2021-12-31 | CN¥7.62 Billion ≈ $1.12 Billion |
+47.75% |
| 2020-12-31 | CN¥5.16 Billion ≈ $754.86 Million |
-1.87% |
| 2019-12-31 | CN¥5.26 Billion ≈ $769.22 Million |
+3.62% |
| 2018-12-31 | CN¥5.07 Billion ≈ $742.36 Million |
+38.25% |
| 2017-12-31 | CN¥3.67 Billion ≈ $536.98 Million |
+51.67% |
| 2016-12-31 | CN¥2.42 Billion ≈ $354.05 Million |
+10.57% |
| 2015-12-31 | CN¥2.19 Billion ≈ $320.20 Million |
+114.99% |
| 2014-12-31 | CN¥1.02 Billion ≈ $148.94 Million |
+1.33% |
| 2013-12-31 | CN¥1.00 Billion ≈ $146.99 Million |
+29.21% |
| 2012-12-31 | CN¥777.41 Million ≈ $113.76 Million |
+134.76% |
| 2011-12-31 | CN¥331.15 Million ≈ $48.46 Million |
+12.17% |
| 2010-12-31 | CN¥295.23 Million ≈ $43.20 Million |
-6.70% |
| 2009-12-31 | CN¥316.43 Million ≈ $46.30 Million |
+111.97% |
| 2008-12-31 | CN¥149.28 Million ≈ $21.84 Million |
-- |
About China Resources Boya Bio pharmaceutical Group Co Ltd
China Resources Boya Bio-pharmaceutical Group Co.,Ltd engages in the blood product businesses in China. It offers blood products, such as human coagulation, human prothrombin, human fibrinogen, human albumin, intravenous human immunoglobulin, and rabies immunoglobulin; and non-blood products. The company also provides bone peptide, oxytocin, heparin sodium, and posterior pituitary injection produ… Read more